All In Biotech

Drug Trial Radar · NCT03841058

Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Phase II Trial of Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Aug 14, 2019

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
Hospital for Special Surgery, New YorkAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective randomized, double-blinded, placebo-controlled, phase 2, 12-month pilot to study the efficacy of abaloparatide in postmenopausal women needing lumbar spinal fusion surgery. A total of 72 women with low bone mass who are scheduled to undergo spinal fusion surgery will be randomized 2:1 in a blinded fashion to receive either 80 mcg of abaloparatide subcutaneously (SC) every day or an identical-appearing placebo SC for 6 months. As well as a total of 24 men in an open-label design will be enrolled as an extension to this study. The total anticipated enrollment updated to 97. Outcomes include surgical outcomes at one year, pain, and fusion bone mass volume (FBMV) as a marker of bone union at 6 months and 1 year.

Conditions

  • Spinal Fusion

Interventions

  • AbaloparatideDrug

    80 mcg delivered SC by a pen

  • PlaceboDrug

    A pen to deliver a SC dose of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in measure of fusion mass bridging from transverse process to transverse processTime frame: one year
  2. Difference in incidence of adverse surgical outcomesTime frame: one year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital for Special Surgery

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.